Emerging therapies for Clostridium difficile infections

Bibliography

• McFarland LV, Beneda HW, Clarridge JE, Raugi GJ. Implications of the changing face of Clostridium difficile disease for health care practitioners. Am J Infect Control 2007;16:237-53
   Web of Science ®Google Scholar
• Hookman P, Barkin JS. Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol 2009;15(13):1554-80
   PubMed Web of Science ®Google Scholar
• McFarland LV. Renewed interest in a difficult disease: Clostridium difficile infections-epidemiology and current treatment strategies. Curr Opin Gastroenterol 2009;25:24-35
   PubMed Web of Science ®Google Scholar
• McFarland LV, Clarridge JE, Beneda HW, Raugi GR. Fluoroquinolone use and risk factors for Clostridium difficile disease within a Veterans Administration Health Care System. Clin Infect Dis 2007;45(9):1141-51
   PubMed Web of Science ®Google Scholar
• Pepin J, Valiquette L, Alary ME, Clostridium difficile–associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004;171:466-72
   PubMed Web of Science ®Google Scholar
• Cohen SH, Gerding DN, Johnson S, Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010;31(5):431-55
   PubMed Web of Science ®Google Scholar
• Zaiss NH, Witte W, Nubel U. Fluoroquinolone resistance and Clostridium difficile, Germany. Emerg Infect Dis 2010;16(4):675-7
   PubMed Web of Science ®Google Scholar
• Sundram F, Guyot A, Carboo I, Clostridium difficile ribotypes 027 and 106: clinical outcomes and risk factors. J Hosp Infect 2009;72(2):111-18
   PubMed Web of Science ®Google Scholar
• O'Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 2007;28(11):1219-27
   PubMed Web of Science ®Google Scholar
• Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect 2008;70(4):298-304
   PubMed Web of Science ®Google Scholar
• Pepin J, Alary ME, Valiquette L, Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005;40:1591-7
   PubMed Web of Science ®Google Scholar
• Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302-7
   PubMed Web of Science ®Google Scholar
• McDonald LC, Coignard B, Dubberke E, ; Ad Hoc Clostridium difficile Surveillance Working Group. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007;28(2):140-5
   PubMed Web of Science ®Google Scholar
• McFarland LV, Surawicz CM, Rubin M, Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999;20:3-50
   Google Scholar
• Noren T, Akerlund T, Back E, Molecular epidemiology of hospital-associated and community-acquired Clostridium difficile infection in a Swedish county. J Clin Microbiol 2004;42(8):3635-43
   PubMed Web of Science ®Google Scholar
• Pelaez T, Cercenado E, Alcala L, Metronidazole resistance in Clostridium difficile is heterogeneous. J Clin Microbiol 2008;46(9):3028-32
   PubMed Web of Science ®Google Scholar
• McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002;97:1769-75
   PubMed Web of Science ®Google Scholar
• McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 2010;16(18):2202-22
   PubMed Web of Science ®Google Scholar
• Parkes GC, Sanderson JD, Whelan K. The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-associated diarrhoea. Lancet Infect Dis 2009;9(4):237-44
   PubMed Web of Science ®Google Scholar
• McFarland LV. Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections. Anaerobe 2009;15(6):274-80
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 2008;14(6):929-31
   PubMed Web of Science ®Google Scholar
• McFarland LV. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol 2008:3(5):563-578
   PubMed Web of Science ®Google Scholar
• Drudy D, Harnedy N, Fanning S, Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive Clostridium difficile. Infect Control Hosp Epidemiol 2007;28(8):932-40
   PubMed Web of Science ®Google Scholar
• Loo VG, Poirier L, Miller MA, A predominantly clonal multi-institutional outbreak of Clostridium-difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-9
   PubMed Web of Science ®Google Scholar
• Beaulieu M, Williamson D, Pichette G, Lachaine J. Risk of Clostridium difficile-associated disease among patients receiving proton-pump inhibitors in a Quebec medical intensive care unit. Infect Control Hosp Epidemiol 2007;28(11):1305-7
   PubMed Web of Science ®Google Scholar
• Jank T, Giesemann T, Aktories K. Rho-glucosylating Clostridium difficile toxins A and B: new insights into structure and function. Glycobiology 2007;17(4):15R-22R
   PubMed Web of Science ®Google Scholar
• Citron DM, Tyrrell KL, Goldstein EJC. In vitro activity of CD-183,315 against 556 strains of C. difficile, 446 strains of intestinal anaerobes, and 56 facultative strains of Enterobacteriaceae. Presented at the 50th ICAAC Meeting; 12 – 15 September 2010; Boston MA
   Google Scholar
• Mortin LI, Van Praagh ADG, Zhang S, Potent efficacy of CB-183,315, a novel lipopeptide antibiotic, in a hamster model of C. difficile infection (CDI). Presented at the 50th ICAAC Meeting; 12 – 15 September 2010; Boston MA
   Google Scholar
• Cubist. CB-183,315 human pharmacokinetics and exposure. Available from: www.cubist.com/downloads/CBST-Investor-Event2010-CDAD. pdf. [Accessed 28 February 2011]
   Google Scholar
• Sullivan KM, Spooner LM. Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection. Ann Pharmacother 2010;44(2):352-9
   PubMed Web of Science ®Google Scholar
• Shue YK, Sears PS, Shangle S, Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob Agents Chemother 2008;52(4):1391-5
   PubMed Web of Science ®Google Scholar
• Louie T, Miller M, Donskey C, Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother 2009;53(1):223-8
   PubMed Web of Science ®Google Scholar
• Gerber M, Ackermann G. OPT-80, a macrocyclic antimicrobial agent for the treatment of Clostridium difficile infections: a review. Expert Opin Investig Drugs 2008;17(4):547-53
   PubMed Web of Science ®Google Scholar
• Louie TJ, Miller MA, Mullane KM, ; OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364(5):422-31
   PubMed Web of Science ®Google Scholar
• Crook D, Miller M, Louie T, Efficacy and safety of fidaxomicin (FDX) vs vancomycin (VAN) in C. difficile infection (CDI) in 2 randomized controlled tirals (RCT) with 1105 patients. Presented at the 48th Annual Meeting of IDSA; 21 – 24 October 2010; Vancouver BC, Canada
   Google Scholar
• Musher DM, Nuila F, Logan N. The long-term outcome of treatment of Clostridium difficile colitis. Clin Infect Dis 2007;45(4):523-4
   PubMed Web of Science ®Google Scholar
• Musher D, Logan N, Hamill RJ, Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006;43:421-31
   PubMed Web of Science ®Google Scholar
• Bartoloni A, Colao MG, Orsi A, In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile. J Antimicrob Chemother 1990;26(5):627-33
   PubMed Web of Science ®Google Scholar
• Fulco P, Wenzel RP. Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent. Expert Rev Anti Infect 2006;4:939-45
   PubMedGoogle Scholar
• Lagrotteria D, Holmes S, Smiega M, Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin Infect Dis 2006;43:547-52
   PubMed Web of Science ®Google Scholar
• Johnson S, Schriever C, Galang M, Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007;44:846-8
   PubMed Web of Science ®Google Scholar
• Tannous G, Neff G, Kemmer N. Therapeutic success of rifaximin for Clostridium difficile infection refractory to metronidazole and vancomycin. Case Rep Gastroenterol 2010;4(3):404-9
   PubMedGoogle Scholar
• Boero M, Berti E, Morgando A, Verme G. Terapia della colite da Clostridium difficile: risultati di uno studio randomizzato aperto ribaximina vs. vancomicina. [Treatment for Clostridium difficile: results of a randomized open study with rifaximine vs. vancomycin.]. Microbiologia Medica 1990;5:74-7
   Google Scholar
• Citron DM, Merriam CV, Tyrrell KL, In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin and four other antimicrobials against intestinal anaerobic bacteria. Antimicrob Agents Chemother 2003;47:2334-8
   PubMed Web of Science ®Google Scholar
• Wenisch C, Parschalk B, Hasenhundl M, Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996;22:813-18
   PubMed Web of Science ®Google Scholar
• SYNSORB Biotech, Inc. Announces Final Phase II Results for SYNSORB.2000. Available from: http://findarticles.com/p/articles/mi_m0EIN/is_2000_July_6/ai_63163411. [Accessed 6 January 2011]
   Google Scholar
• Weiss K. Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer. Int J Antimicrob Agents 2009;33(1):4-7
   PubMed Web of Science ®Google Scholar
• Louie TJ, Peppe J, Watt CK, ; for the tolevamer study investigator group. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile associated diarrhea. Clin Infect Dis 2006;43:411-20
   PubMed Web of Science ®Google Scholar
• Louie TJ, Gerson M, Grimard D, Results of a phase III study comparing tolevamer, vancomycin and metronidazole in CDAD [abstact K-4259]. In: program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 17 – 20 September 2007; ASM Press, Chicago IL; Washington DC; 2007
   Google Scholar
• Laffan AM, McKenzie R, Geenough WB, Lactoferrin for the prevention of CDAD. Abstract presented at 2009 American Gastro Society Meeting; 20 – 25 October 2006; Las Vegas NV
   Google Scholar
• Elmer GW, McFarland LV, McFarland M. The power of probiotics: improving your health with beneficial microbes. Haworth Press, Binghamton, NY; 2007
   Google Scholar
• Plummer S, Weaver MA, Harris JC, Clostridium difficile pilot study: effects of probiotoic supplementation on the incidence of Clostridium difficile diarrhoea. Int Microbiol 2004;7:59-62
   PubMed Web of Science ®Google Scholar
• Rafiq R, Randey D, Osman SM, Prevention of Clostridium difficile (C. difficile) diarrhea with probiotic in hospitalized patients treated with antibiotics. AGA Meeting; 2007. Gastroenterol 2007;132:A187 [S1167]
   Google Scholar
• Lewis SJ, Potts LF, Barry RE. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients. J Infect 1998;36:171-4
   PubMed Web of Science ®Google Scholar
• Thomas MR, Litin SC, Osmon DR, Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial. Mayo Clin Proc 2001;76:883-9
   PubMed Web of Science ®Google Scholar
• Hickson M, D'Souza AL, Muthu N, Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007;335(7610):80
   PubMed Web of Science ®Google Scholar
• Gao XW, Mubasher M, Fang CY, Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010;105(7):1636-41
   PubMed Web of Science ®Google Scholar
• Lawrence SJ, Korzenik JR, Mundy LM. Probiotics for recurrent Clostridium difficile disease. J Med Microbiol 2005;54(Pt 9):905-6
   PubMed Web of Science ®Google Scholar
• Pochapin M. The effect of probiotics on Clostridium difficile diarrhea. Am J Gastroenterol 2000;95(S1):S11-13
   PubMed Web of Science ®Google Scholar
• Wullt M, Hagslatt MJ, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis 2003;35:365-67
   PubMed Web of Science ®Google Scholar
• McFarland LV, Surawicz CM, Greenberg RN, A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994;271:1913-18
   PubMed Web of Science ®Google Scholar
• Surawicz CM, McFarland LV, Greenberg RN, The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000;31:1012-17
   PubMed Web of Science ®Google Scholar
• Bakken JS. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe 2009;15(6):285-9
   PubMed Web of Science ®Google Scholar
• van Nood E, Speelman P, Kuijper EJ, Keller JJ. Struggling with recurrent Clostridium difficile infections: is donor faeces the solution? Euro Surveill 2009;14(34):16
   PubMedGoogle Scholar
• Odenholt I, Walder M, Wullt M. Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against Clostridium difficile. Chemotherapy 2007;53(4):267-74
   PubMed Web of Science ®Google Scholar
• Wullt M, Odenholt I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated dharrhoea. J Antimicrob Chemother 2004;54:211-16
   PubMed Web of Science ®Google Scholar
• Noren T, Wullt M, Akerlund T, Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid. Antimicrob Agents Chemother 2006;50(9):3028-32
   PubMed Web of Science ®Google Scholar
• Abougergi MS, Broor A, Cui W, Jaar BG. Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature. J Hosp Med 2010;5(1):e1-9
   PubMedGoogle Scholar
• Juang P, Skledar SJ, Zgheib NK, Clinical outcomes of intravenous immune globulin in severe Clostridium difficile-associated diarrhea. Am J Infect Control 2007;35:131-7
   PubMed Web of Science ®Google Scholar
• Kelly CP, Chetham S, Keates S, Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract. Antimicrob Agents Chemother 1997;41:236-41
   PubMed Web of Science ®Google Scholar
• Warny M, Fatimi A, Bostwick EF, Bovine immunoglobulin concentrate-Clostridium difficile retains C. difficile toxin neutralising activity after passage through the human stomach and small intestine. Gut 1999;44:212-17
   PubMed Web of Science ®Google Scholar
• Young KW, Munro IC, Taylor SL, The safety of whey protein concentrate derived from the milk of cows immunized against Clostridium difficile. Regul Toxicol Pharmacol 2007;47:317-26
   PubMed Web of Science ®Google Scholar
• Van Dissel JT, De Groot N, Hensgens CM, Bovine antibody-enriched whey to aid in the prevention of relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data. J Med Microbiol 2005;54:197-205
   PubMed Web of Science ®Google Scholar
• Numan SC, Veldkamp P, Kuijper EJ, Clostridium difficile-associated diarrhea: bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses. Gut 2007;56:888-9
   PubMed Web of Science ®Google Scholar
• Leav BA, Blair B, Leney M, Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 2010;28(4):965-9
   PubMed Web of Science ®Google Scholar
• Lowy I, Molrine DC, Leav BA, Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010;362(3):197-205
   PubMed Web of Science ®Google Scholar
• Field D, Hill C, Cotter PD, Ross RP. The dawning of a ‘golden era’ in lantbiotic bioengineering. Microreview. Mol Microbiol 2010;78(5):1077-87
   PubMed Web of Science ®Google Scholar
• Huscroft GS, Baines SD, Todhunter SL, NVB302 demonstrates non-inferiority to vancomycin in treatment of C. difficile NAP1/027 infection in an in vitro human gut model. Presented at the 50th ICAAC Meeting; 12 – 15 September 2010; Boston MA
   Google Scholar
• Mkrtchyan H, Gibbons S, Heidelberger S, Purification, characterisation and identification of acidocin LCHV, an antimicrobial peptide produced by Lactobacillus acidophilus n.v. Er 317/402 strain Narine. Int J Antimicrob Agents 2010;35(3):255-60
   PubMed Web of Science ®Google Scholar
• Rea MC, Sit CS, Clayton E, Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. Proc Natl Acad Sci USA 2010;107(20):9352-7
   PubMed Web of Science ®Google Scholar
• Baines SD, O'Connor R, Saxton K, Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model. J Antimicrob Chemother 2008;62(5):1078-85
   PubMed Web of Science ®Google Scholar
• Marquis M, Higgins ME, Mong SM, Lehoux D. Oritavancin pretreatment does not induce C. difficile infection in an experimental hamster model. Presented at the 50th ICAAC Meeting; 12 – 15 September 2010; Boston MA
   Google Scholar
• Citron DM, Warren YA, Tyrrell KL, Comparative in vitro activity of REP3123 against Clostridium difficile and other anaerobic intestinal bacteria. J Antimicrob Chemother 2009;63(5):972-6
   PubMed Web of Science ®Google Scholar
• Ochsner UA, Bell SJ, O'Leary AL, Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model. J Antimicrob Chemother 2009;63(5):964-71
   PubMed Web of Science ®Google Scholar
• Nagy E, Dowzicky MJ. In vitro activity of tigecycline and comparators against a European compilation of anaerobes collected as part of the Tigecycline Evaluation and Surveillance Trial (TEST). Scand J Infect Dis 2010;42(1):33-8
   PubMed Web of Science ®Google Scholar
• Herpers BL, Vlaminckx B, Burkhardt O, Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 2009;48(12):1732-5
   PubMed Web of Science ®Google Scholar
• Kotloff KL, Wasserman SS, Losonsky GA, Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 2001;69:988-95
   PubMed Web of Science ®Google Scholar
• Stiefel U, Nerandzic MM, Koski P, Donskey CJ. Orally administered beta-lactamase enzymes represent a novel strategy to prevent colonization by Clostridium difficile. J Antimicrob Chemother 2008;62(5):1105-8
   PubMed Web of Science ®Google Scholar